BioAge Labs (NasdaqGS:BIOA) FY Conference September 10, 2025 10:00 AM ET Company ParticipantsKristen Fortney - CEO and Co-founderDov Goldstein - CFOConference Call ParticipantsMike Goldstein - Biotech AnalystMike GoldsteinAll right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Health Care Conference. I'm Mike Goldstein, the biotech analyst here, and it's my pleasure to introduce the team from BioAge Labs, Kristen Fortney, CEO and co-founder, as well as Dov Goldstein, CFO. J ...

BioAge Labs (BIOA) Conference Summary Company Overview - BioAge Labs focuses on understanding mechanisms of aging and metabolic aging using longitudinal human data from biobanks [4][5] - The company has collaborations with Novartis and Lilly for target discovery and drug development [5] Key Programs and Developments NLRP3 Program (BGE 102) - BGE 102 is an oral, CNS-penetrant molecule targeting obesity, with potential best-in-class properties [6][7] - The molecule shows high potency in inhibiting IL-1 beta and has a novel binding site on NLRP3 [7][10] - Preclinical data indicates significant weight loss effects comparable to semaglutide, both as a monotherapy and in combination with incretin therapies [18][19][31] - The mechanism of action involves appetite suppression driven by neuroinflammation [15][16] - A Phase 1 study has commenced, with expected data on safety and IL-1 beta inhibition by the end of the year [23][25] APJ Program - The APJ program includes alternative oral small molecules and a nanobody, aiming to amplify weight loss and preserve muscle [51][52] - The goal is to file an IND for the oral small molecules next year, with potential for a monthly dosing regimen for the nanobody [52][66] - APJ has shown preclinical and clinical potential in preserving muscle, particularly in older populations [55][60] Market Position and Competitive Landscape - The oral obesity treatment market is considered wide open, with significant room for novel mechanisms [35] - BioAge aims to differentiate itself by combining mechanisms that enhance weight loss while maintaining tolerability [39] - The company is closely monitoring competitors' readouts, particularly from Ventex and Nodthera, to inform its strategy [34][41] Financial Outlook - As of June, BioAge had approximately $313 million in cash, providing a runway of over three years [89] - The company is focused on capitalizing on partnerships and collaborations to lower costs and enhance funding opportunities [90][91] Strategic Vision - BioAge envisions advancing a portfolio of differentiated mechanisms into clinical trials, targeting obesity and its comorbidities [80] - The company is exploring additional partnerships and collaborations to expand its pipeline and capabilities [78][79] Conclusion - BioAge Labs is positioned to be a leader in the obesity treatment space with its innovative approaches and strong pipeline, focusing on both NLRP3 and APJ mechanisms [100][101]